OptiBiotix Health reported significant progress in its commercial endeavours in an update on Wednesday, as it looked to attain profitability at the business unit level, ultimately leading to overall profitability.
Life sciences developer OptiBiotix Health announced a significant agreement with Tata Chemicals on Monday, that would see its proprietary ‘Fossence’ product incorporated into their ‘SlimBiome’ and ‘LeanBiome’ product lines, specifically tailored for the Indian market.
OptiBiotix Health PLC on Monday said it agreed a licence deal with Tata Chemicals Ltd to incorporate Tata s short-chain fructo-oligosaccharide Fossence into OptiBiotix s SlimBiome and LeanBiome.
Shares in OptiBiotix Health PLC (AIM:OPTI, OTC:OPBXF) climbed by 12% on Monday morning after the firm unveiled a licensing agreement with Tata Chemicals to.